Novavax, Inc. (NVAX)

NASDAQ: NVAX · IEX Real-Time Price · USD
-0.100 (-2.51%)
Apr 17, 2024, 4:00 PM EDT - Market closed
Market Cap 544.42M
Revenue (ttm) 983.71M
Net Income (ttm) -545.06M
Shares Out 139.95M
EPS (ttm) -5.41
PE Ratio n/a
Forward PE 1.78
Dividend n/a
Ex-Dividend Date n/a
Volume 3,659,201
Open 4.000
Previous Close 3.990
Day's Range 3.880 - 4.050
52-Week Range 3.530 - 11.360
Beta 1.60
Analysts Strong Buy
Price Target 17.00 (+337.02%)
Earnings Date May 7, 2024

About NVAX

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand n... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Dec 5, 1995
Employees 1,543
Stock Exchange NASDAQ
Ticker Symbol NVAX
Full Company Profile

Financial Performance

In 2023, Novavax's revenue was $983.71 million, a decrease of -50.36% compared to the previous year's $1.98 billion. Losses were -$545.06 million, -17.16% less than in 2022.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for NVAX stock is "Strong Buy." The 12-month stock price forecast is $17.0, which is an increase of 337.02% from the latest price.

Price Target
(337.02% upside)
Analyst Consensus: Strong Buy
Stock Forecasts


Levi & Korsinsky, LLP Notifies Shareholders of Novavax, Inc. (NVAX) an Upcoming Claims Deadline in a Class Action Settlement

NEW YORK, NY / ACCESSWIRE / April 16, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Novavax, Inc. (NASDAQ: NVAX). The sett...

1 day ago - Accesswire

Hedge fund Shah Capital recommends two new candidates for Novavax board

U.S.-based hedge fund Shah Capital on Monday recommended the appointment of two new independent directors to the Novavax board.

2 days ago - Reuters

Novavax failed to capitalize on fears surrounding mRNA vaccines, activist investor says

Hedge fund Shah Capital on Monday called for an “urgent shake up” at the board of Novavax over claims its management has failed to capitalize on safety concerns surrounding mRNA vaccines to boost sale...

2 days ago - Market Watch

Novavax Presents Data on Updated COVID-19 Vaccine and Progress to Date on its COVID-19-Influenza Combination Vaccine Candidate at World Vaccine Congress 2024

GAITHERSBURG, Md. , April 1, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, will showcase continued progress on data ...

16 days ago - PRNewsWire

Novavax to Participate in TD Cowen's 44th Annual Health Care Conference

GAITHERSBURG, Md. , Feb. 29, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in TD...

6 weeks ago - PRNewsWire

Novavax Stock Sinks as Revenue Misses Estimates in ‘Transition Year'

Novavax posts a fourth-quarter loss of $1.44 a share on revenue of $291.3 million.

7 weeks ago - Barrons

Novavax sees 2024 sales flat to lower, aims to pick up COVID vaccine market share

COVID-19 vaccine maker Novavax on Wednesday said it expects revenue this year to be flat or lower as it works to improve its commercial performance and pick up market share from much larger rivals, Pf...

7 weeks ago - Reuters

Novavax misses quarterly estimates, but vaccine maker narrows losses as it slashes costs

Novavax narrowed its losses in the quarter compared to the same period a year ago, even as demand for Covid products continues to plummet worldwide.

7 weeks ago - CNBC

Novavax Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

Achieved revenues in Q4 2023 of $291 million and full year 2023 of $1.0 billion Accelerating progress toward expanding pipeline  via Phase 3 COVID-19-Influenza Combination vaccine trial in second half...

7 weeks ago - PRNewsWire

Novavax stock surges after resolving Gavi vaccine dispute

Vaccine developer Novavax (NVAX) is seeing its stock skyrocket after resolving a dispute with the global nonprofit vaccine alliance Gavi. In an agreement, Novavax has refunded a large portion of Gavi'...

7 weeks ago - Yahoo Finance

Novavax Stock Soars 25%. A Vaccine Purchase Settlement Is One Reason Why.

Novavax reaches a settlement related to an advance purchase agreement with Gavi.

7 weeks ago - Barrons

Novavax to settle dispute over canceled Covid vaccine purchase agreement

The total amount Novavax will pay depends on whether Gavi decides to order more Covid shots from the cash-strapped company over the next five years.

7 weeks ago - CNBC

Novavax settles dispute with international vaccine group Gavi

Novavax said on Thursday it has agreed to pay back international vaccine group Gavi at least $475 million in cash or vaccines by the end of 2028, settling a dispute over canceled orders that had creat...

7 weeks ago - Reuters

Novavax and Gavi Reach Settlement on 2021 COVID-19 Vaccine Advance Purchase Agreement

GAITHERSBURG, Md. and GENEVA , Feb. 22, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) and Gavi, the Vaccine Alliance (Gavi) today announced they have reached a settlement related to the 2021 Advan...

7 weeks ago - PRNewsWire

Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights on February 28, 2024

GAITHERSBURG, Md. , Feb. 20, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its fourth...

2 months ago - PRNewsWire

Novavax to cut 12% of global workforce

Vaccine maker Novavax said on Wednesday it will reduce its total global workforce by about 12% as part of its ongoing efforts to reduce costs.

2 months ago - Reuters

Novavax to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

GAITHERSBURG, Md. , Jan. 3, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it will participate i...

3 months ago - PRNewsWire

Short Sellers Think These Stocks Will Tank in 2024. Investors Can Bet Otherwise.

The number of shorted shares has grown 23% since the end of 2020, but that doesn't mean traders are getting more bearish about the market.

3 months ago - Barrons

Novavax's Updated COVID-19 Vaccine Receives Emergency Use Authorization in Taiwan

Novavax's updated vaccine will be available at vaccination centers across Taiwan GAITHERSBURG, Md. , Dec. 18, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-base...

4 months ago - PRNewsWire

Health Canada authorizes Novavax's updated COVID shot for Omicron

Novavax said on Tuesday that Health Canada had authorized its updated COVID-19 vaccine, targeting the Omicron subvariant XBB.1.5, in individuals aged 12 years and older.

4 months ago - Reuters

Novavax's Updated COVID-19 Vaccine Now Authorized in Canada

Novavax's updated protein-based non-mRNA COVID-19 vaccine will be available in Canada for individuals aged 12 and older in the coming days GAITHERSBURG, Md. , Dec. 5, 2023 /PRNewswire/ -- Novavax, Inc...

4 months ago - PRNewsWire

Covid vaccine rates in the U.S. are slumping — and it will be a challenge to boost them

The one thing that experts, along with vaccine makers, can agree on is that low vaccination rates put people at risk of getting severe Covid infections.

Other symbols: MRNAPFE
4 months ago - CNBC

WHO authorizes emergency use of Novavax's updated COVID vaccine

Novavax's updated vaccine has been granted emergency-use authorization by the World Health Organization (WHO) for active immunization to prevent COVID-19 in individuals aged 12 and older, the company ...

5 months ago - Reuters

Novavax's stock pops after WHO grants its COVID-19 vaccine emergency-use listing

Novavax Inc.'s stock NVAX soared 4.6% early Tuesday, after the company said its protein-based COVID-19 vaccine had been granted emergency-use listing by the World Health Organization. The move means t...

5 months ago - Market Watch

Novavax's Updated Protein-based COVID-19 Vaccine Now an Option for All 194 Member States of the World Health Organization

GAITHERSBURG, Md. , Nov. 28, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that Nuvaxovid™ XBB.1.5 C...

5 months ago - PRNewsWire